Experimental immune therapy aims to reduce deaths in severe pneumonia
NCT ID NCT07615010
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tests whether a single dose of an experimental immune cell therapy called agenT-797, given alongside standard care, can lower the risk of death in adults with severe pneumonia and breathing failure. About 90 people in intensive care will receive either agenT-797 or a placebo, plus usual treatments like antibiotics and steroids. The main goal is to see if more people survive with the added therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
agenT-797 (an experimental immune cell therapy given as a single intravenous infusion)
What this could lead to
If it works, this could point toward a new treatment to reduce deaths from severe pneumonia with respiratory failure.
What could go wrong
This is a small, early Phase 2 trial with only 90 participants, so results may not apply broadly. The treatment is experimental and may not improve survival or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Memorial Hermann Hospital
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact
-
First Lviv Territorial Medical Union
RECRUITINGLviv, 79059, Ukraine
Contact
-
UCSF Medical Center at Parnassus Heights
NOT_YET_RECRUITINGSan Francisco, California, 94143, United States
Contact
-
University Hospital
NOT_YET_RECRUITINGSan Antonio, Texas, 78229, United States
Contact